For pharma, biotech and CRO teams

Develop models around the decision they must support.

JetBio manufactures and sells configurable 3D bioprinting systems with control software, installation, training and application support. We work from a defined drug-development question towards a fit-for-purpose model and reproducible workflow.

JetBio printhead positioned above a multiwell plate

A decision-led starting point

Define the context before developing the model.

The same model cannot answer every discovery, efficacy or safety question. A credible programme states where the model will be used, what it will measure and what decision its output may inform.

CONTEXT

Specify the programme decision

Connect the biological endpoint to a defined stage, therapeutic question and action.

MODEL

Design for human relevance

Select cells, materials, architecture and culture conditions around the biology that matters.

TRANSFER

Plan for repeatable use

Include operators, formats, throughput, controls, readouts and transfer requirements in the development brief.

Precision nozzles on JetBio bioprinting technology

Applications-led modularity

Use the print mode the biology requires.

JetBio supplies one supported system with reactive jet impingement, microvalve and inkjet development modes. The configured workflow may use one mode or combine complementary capabilities, subject to material compatibility and the required model architecture.

Disease modellingAssay developmentSelected safety researchMultiwell workflows
Explore the platform

Evidence requirements

Build towards adoption, not a one-off demonstration.

Define during scoping

  • Biological question and intended decision
  • Reference method, controls and comparator
  • Required format, throughput and readout
  • Acceptance criteria and evidence threshold
  • IP, confidentiality and data responsibilities

Test during development

  • Model performance and biological relevance
  • Within-run and between-run reproducibility
  • Operator, equipment and workflow robustness
  • Scalability and transfer across the intended setting
  • Support, training and change-control needs

The ABPI and NC3Rs identify robustness, validation, standardisation and scalability as central gaps between promising academic models and routine pharmaceutical use. JetBio does not represent research deployments as qualified drug-development tools.

Read the ABPI and NC3Rs landscape review

Commercial pathway

De-risk the application before procurement.

  1. 01

    Confidential discovery

    Align on therapeutic area, programme stage, current model and decision need.

  2. 02

    Feasibility brief

    Define materials, format, comparator, controls, evidence gates, responsibilities and commercial terms.

  3. 03

    Application project

    Generate relevant evidence against a bounded work package and record limitations as well as results.

  4. 04

    Procure and implement

    Review the evidence and operational fit, then agree the system configuration, software workflow, installation, training and support.

Frequently asked questions

Questions drug-development teams ask first.

Where could JetBio fit in a drug-discovery workflow?

Potential uses include disease-model development, target and mechanism research, assay development and selected safety or efficacy studies. The relevant use must be defined for each programme rather than assumed from the technology alone.

Does JetBio claim that its models replace animal studies?

No. Human-relevant in vitro models may reduce or replace animal use in defined contexts, but that requires suitable evidence, validation and, where applicable, regulatory engagement. JetBio does not make a blanket replacement claim.

Can JetBio support throughput and multiwell formats?

Selected multiwell workflows form part of the development pathway. Required plate format, replicate number, handling, readout and automation interfaces must be assessed during scoping.

What is the first commercial step?

The usual starting point is a confidential fit discussion followed, where appropriate, by a scoped feasibility or application-development project with agreed evidence gates.

Enquiry form

Define the drug-development question.

Share the context of use, current model, readout, format, throughput and evidence threshold for a confidential fit review.

Please do not include confidential, personal health or unpublished research data.

Start a useful conversation

Evaluate a JetBio system for your workflow.

Review the modular architecture, software and support offer, then define the evidence needed for a procurement decision.

Discuss a system